JUNB and neoplasm: For example, in triple-negative breast cancer (TNBC), NAT10 enhances JunB mRNA stability through ac4C modification, drives the upregulation of LDHA expression, promotes glycolysis and lactate accumulation, inhibits T-cell activation and accelerates tumor progression, whereas the NAT10 inhibitor Remodelin reduces LDHA expression, remodels the tumor microenvironment, and effectively inhibits tumor growth and lung metastasis.